Iovance's BLA for Advanced Melanoma Therapeutic Delayed Until Q1 2023

The FDA has delayed Iovance Biotherapeutics's Biologics License Application for lifileucel, a treatment for unresectable or metastatic melanoma, until Q1 of 2023.

The delay was due to the agency's request for additional data on the drug, Iovance announced Friday.